Biomarkers for early detection of liver cancer: Focus on clinical evaluation

Protein and Peptide Letters

Volumn 16, Issue 5, 2009, Pages 473-478

  Sun, Stella ^a   Day, Philip J R ^b   Lee, Nikki P ^a   Luk, John M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diagnostic imaging; Early cancer detection network; Hepatocellular carcinoma; Serological biomarkers

Indexed keywords

TUMOR MARKER;

ANIMAL; ARTICLE; BLOOD; CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; HUMAN; LIVER TUMOR; METABOLISM; RADIOGRAPHY; SEROLOGY;

ANIMALS; DIAGNOSTIC IMAGING; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; SEROLOGIC TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649306596     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986609788167888     Document Type: Article

References (52)

1. Tang, Z. Y.; Ye, S. L.; Liu, Y. K.; Qin, L. X.; Sun, H. C.; Ye, Q. H.; Wang, L.; Zhou, J.; Qiu, S. J.; Li, Y.; Ji, X. N.; Liu, H.; Xia, J.L.; Wu, Z. Q.; Fan, J.; Ma, Z. C.; Zhou, X. D.; Lin, Z. Y.; Liu, K.D. A decade's studies on metastasis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 2004, 130(4), 187-96.
2. Feng, J. T.; Shang, S.; Beretta, L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene, 2006, 25(27), 3810-7.
3. Conrad, D. H.; Goyette, J.; Thomas, P. S. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J. Gen. Intern. Med., 2008, 23 (Suppl 1), 78-84.
4. Visintin, I.; Feng, Z.; Longton, G.; Ward, D. C.; Alvero, A. B.; Lai,Y.; Tenthorey, J.; Leiser, A.; Flores-Saaib, R.; Yu, H.; Azori, M.; Rutherford, T.; Schwartz, P. E.; Mor, G. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res., 2008, 14(4), 1065-72.
5. Laxman, B.; Morris, D. S.; Yu, J.; Siddiqui, J.; Cao, J.; Mehra, R.; Lonigro, R. J.; Tsodikov, A.; Wei, J. T.; Tomlins, S. A.; Chinnai- yan, A. M. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res., 2008, 68(3),645-9.
6. Wu, F. S.; Zhao, W. H.; Liang, T. B.; Ma, Z. M.; Teng, L. S.;Wang, M.; Zheng, S. S. Survival factors after resection of small he- patocellular carcinoma. Hepatobiliary Pancreat. Dis. Int., 2005, 4(3), 379-84.
7. Marrero, J. A.; Lok, A. S. Newer markers for hepatocellular carcinoma. Gastroenterology, 2004, 127, 5 (Suppl 1), S113-9.
8. Zoli, M.; Magalotti, D.; Bianchi, G.; Gueli, C.; Marchesini, G.; Pisi, E. Efficacy of a surveillance program for early detection of hepato- cellular carcinoma. Cancer, 1996, 78(5), 977-85.
9. Takayama, T.; Makuuchi, M.; Hirohashi, S.; Sakamoto, M.; Ya- mamoto, J.; Shimada, K.; Kosuge, T.; Okada, S.; Takayasu, K.; Yamasaki, S. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology, 1998, 28(5), 1241-6.
10. Zinkin, N. T.; Grall, F.; Bhaskar, K.; Otu, H. H.; Spentzos, D.; Kalmowitz, B.; Wells, M.; Guerrero, M.; Asara, J. M.; Libermann, T. A.; Afdhal, N. H. Serum Proteomics and Biomarkers in Hepato- cellular Carcinoma and Chronic Liver Disease. Clin. Cancer Res., 2008, 14(2), 470-477.
11. Willatt, J. M.; Hussain, H. K.; Adusumilli, S.; Marrero, J. A. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: chal lenges and controversies. Radiology, 2008, 247(2), 311-30.
12. Saar, B.; Kellner-Weldon, F. Radiological diagnosis of hepatocellu- lar carcinoma. Liver Int., 2008, 28(2), 189-99.
13. Bennett, G. L.; Krinsky, G. A.; Abitbol, R. J.; Kim, S. Y.; Theise, N. D.; Teperman, L. W. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pre- transplantation sonography and liver explant pathology in 200 patients. AJR Am. J. Roentgenol., 2002, 179(1), 75-80.
14. Takayama, T.; Makuuchi, M.; Kojiro, M.; Lauwers, G. Y.; Adams, R. B.; Wilson, S. R.; Jang, H. J.; Charnsangavej, C.; Taouli, B. Early hepatocellular carcinoma: pathology, imaging, and therapy.Ann. Surg. Oncol., 2008, 15(4), 972-8.
15. Bast, R. C., Jr.; Lilja, H.; Urban, N.; Rimm, D. L.; Fritsche, H.;Gray, J.; Veltri, R.; Klee, G.; Allen, A.; Kim, N.; Gutman, S.; Rubin, M. A.; Hruszkewycz, A. Translational crossroads for biomark- ers. Clin. Cancer Res., 2005, 11(17), 6103-8.
16. He, Q. Y.; Zhu, R.; Lei, T.; Ng, M. Y.; Luk, J. M.; Sham, P.; Lau, G. K.; Chiu, J. F. Toward the proteomic identification of biomark- ers for the prediction of HBV related hepatocellular carcinoma. J. CellBiochem., 2008, 103(3), 740-52.
17. Trevisani, F.; De, N. S.; Rapaccini, G.; Farinati, F.; Benvegnu, L.Zoli, M.; Grazi, G. L.; Del, P. P.; Di, N.; Bernardi, M. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am. J. Gastroenterol., 2002, 97(3), 734-44.
18. Zhou, L.; Liu, J.; Luo, F. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol., 2006, 12(8), 1175-81.
19. Bruix, J.; Sherman, M.; Llovet, J. M.; Beaugrand, M.; Lencioni, R.; Burroughs, A. K.; Christensen, E.; Pagliaro, L.; Colombo, M.; Rodes, J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol., 2001, 35(3), 421-30.
20. Chen, T. M.; Huang, P. T.; Tsai, M. H.; Lin, L. F.; Liu, C. C.; Ho,K. S.; Siauw, C. P.; Chao, P. L.; Tung, J. N. Predictors of alpha- fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated in- terferon alfa 2a-ribavirin combination therapy. J. Gastroenterol. Hepatol., 2007, 22(5), 669-75.
21. Mazzaferro, V.; Regalia, E.; Doci, R.; Andreola, S.; Pulvirenti, A.; Bozzetti, F.; Montalto, F.; Ammatuna, M.; Morabito, A.; Gennari, L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med., 1996, 334(11), 693-9.
22. Miyaaki, H.; Nakashima, O.; Kurogi, M.; Eguchi, K.; Kojiro, M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepato- cellular carcinoma. J. Gastroenterol., 2007, 42(12), 962-8.
23. Durazo, F. A.; Blatt, L. M.; Corey, W. G.; Lin, J. H.; Han, S.; Saab,S.; Busuttil, R. W.; Tong, M. J. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol.,2008, 23, 1541-48.
24. Bachert, C.; Fimmel, C.; Linstedt, A. D. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic, 2007, 8(10), 1415-23.
25. Kladney, R. D.; Bulla, G. A.; Guo, L.; Mason, A. L.; Tollefson, A. E.; Simon, D. J.; Koutoubi, Z.; Fimmel, C. J. GP73, a novel Golgi- localized protein upregulated by viral infection. Gene, 2000, 249(1- 2), 53-65.
26. Marrero, J. A.; Romano, P. R.; Nikolaeva, O.; Steel, L.; Mehta, A.; Fimmel, C. J.; Comunale, M. A.; D'Amelio, A.; Lok, A. S.; Block, T. M. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol., 2005, 43(6), 1007-12.
27. Toyoda, H.; Kumada, T.; Osaki, Y.; Oka, H.; Kudo, M. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol. Res., 2007, 37 (Suppl 2), S166-71.
28. Kim do, Y.; Paik, Y. H.; Ahn, S. H.; Youn, Y. J.; Choi, J. W.; Kim, J. K.; Lee, K. S.; Chon, C. Y.; Han, K. H. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology, 2007, 72 (Suppl 1), 52-7.
29. Giannelli, G.; Marinosci, F.; Trerotoli, P.; Volpe, A.; Quaranta, M.; Dentico, P.; Antonaci, S. SCCA antigen combined with alpha- fetoprotein as serologic markers of HCC. Int. J. Cancer, 2005,117(3), 506-9.
30. Izuno, K.; Fujiyama, S.; Yamasaki, K.; Sato, M.; Sato, T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha- fetoprotein: a prospective study. Hepatogastroenterology, 1995,42(4), 387-93.
31. Miura, N.; Maruyama, S.; Oyama, K.; Horie, Y.; Kohno, M.; Noma, E.; Sakaguchi, S.; Nagashima, M.; Kudo, M.; Kishimoto, Y.; Kawasaki, H.; Hasegawa, J.; Shiota, G. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepato- cellular carcinoma. Oncology, 2007, 72 (Suppl 1), 45-51.
32. Cillo, U.; Vitale, A.; Navaglia, F.; Basso, D.; Montin, U.; Bassanello, M.; D'Amico, F.; Ciarleglio, F. A.; Brolese, A.; Zanus, G.; DePascale, V.; Plebani, M.; D'Amico, D. F. Role of blood AFP mRNAand tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J. Gastroenterol., 2005,11(44), 6920-5.
33. Capurro, M.; Wanless, I. R.; Sherman, M.; Deboer, G.; Shi, W.; Miyoshi, E.; Filmus, J. Glypican-3: a novel serum and histochemi- cal marker for hepatocellular carcinoma. Gastroenterology, 2003, 125(1), 89-97.
34. Kandil, D.; Leiman, G.; Allegretta, M.; Trotman, W.; Pantanowitz, L.; Goulart, R.; Evans, M. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer, 2007, 111(5), 316-22.
35. Hippo, Y.; Watanabe, K.; Watanabe, A.; Midorikawa, Y.; Yama- moto, S.; Ihara, S.; Tokita, S.; Iwanari, H.; Ito, Y.; Nakano, K.; Nezu, J.; Tsunoda, H.; Yoshino, T.; Ohizumi, I.; Tsuchiya, M.; Oh- nishi, S.; Makuuchi, M.; Hamakubo, T.; Kodama, T.; Aburatani, H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res., 2004, 64(7), 2418-23.
36. Yang, Z. F.; Ho, D. W.; Lam, C. T.; Luk, J. M.; Lum, C. T.; Yu, W.C.; Poon, R. T.; Fan, S. T. Identification of brain-derived neurotro- phic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res., 2005, 65(1), 219-25.
37. Yang, Z. F.; Ho, D. W.; Lau, C. K.; Tam, K. H.; Lam, C. T.; Yu, W. C.; Poon, R. T.; Fan, S. T. Significance of the serum brain- derived neurotrophic factor and platelets in hepatocellular carcinoma. Oncol. Rep., 2006, 16(6), 1237-43. [
38. 38]Giannelli, G.; Fransvea, E.; Trerotoli, P.; Beaugrand, M.; Marino- sci, F.; Lupo, L.; Nkontchou, G.; Dentico, P.; Antonaci, S. Clinical validation of combined serological biomarkers for improved hepa- tocellular carcinoma diagnosis in 961 patients. Clin. Chim. Acta., 2007, 383(1-2), 147-52.
39. Scholz, A.; Rehm, V. A.; Rieke, S.; Derkow, K.; Schulz, P.; Neumann, K.; Koch, I.; Pascu, M.; Wiedenmann, B.; Berg, T.; Schott, E. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am. J. Gastroenterol., 2007, 102(11), 2471-81.
40. Pepe, M. S.; Etzioni, R.; Feng, Z.; Potter, J. D.; Thompson, M. L.;Thornquist, M.; Winget, M.; Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst., 2001, 93(14), 1054-61.
41. Sun, S.; Lee, N. P.; Poon, R. T.; Fan, S. T.; He, Q. Y.; Lau, G. K.;Luk, J. M. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int., 2007,27(8), 1021-38.
42. Lee, N. P., Cheung, S. T., Poon, R. T., Fan, S. T. and Luk, J. M.Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomarkers Med., 2007, 1, 273-284.
43. Gagnon, A.; Kim, J. H.; Schorge, J. O.; Ye, B.; Liu, B.; Hasselblatt,K.; Welch, W. R.; Bandera, C. A.; Mok, S. C. Use of a Combination of Approaches to Identify and Validate Relevant Tumor- Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients. Clin. Cancer Res., 2008, 14(3), 764-771.
44. Mazziotti, G.; Sorvillo, F.; Morisco, F.; Carbone, A.; Rotondi, M.; Stornaiuolo, G.; Precone, D. F.; Cioffi, M.; Gaeta, G. B.; Caporaso, N.; Carella, C. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer, 2002, 95(12), 2539-45.
45. Yamagamim, H.; Moriyama, M.; Matsumura, H.; Aoki, H.; Shi- mizu, T.; Saito, T.; Kaneko, M.; Shioda, A.; Tanaka, N.; Arakawa, Y. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer, 2002, 95(4), 824-34.
46. Takayasu, K.; Muramatsu, Y.; Mizuguchi, Y.; Ojima, H. CT Imaging of early hepatocellular carcinoma and the natural outcome of hypoattenuating nodular lesions in chronic liver disease. Oncology,2007,72 (Suppl 1), 83-91.
47. Zhao, H.; Yao, J. L.; Wang, Y.; Zhou, K. R. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J. Gastroenterol., 2007, 13(8), 1252-6.
48. Kim, S. R.; Ando, K.; Mita, K.; Fuki, S.; Ikawa, H.; Kanbara, Y.;Imoto, S.; Matsuoka, T.; Hayashi, Y.; Kudo, M. Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm.Oncology, 2007, 72 (Suppl 1), 58-66.
49. Gaiani, S.; Celli, N.; Piscaglia, F.; Cecilioni, L.; Losinno, F.; Gian- gregorio, F.; Mancini, M.; Pini, P.; Fornari, F.; Bolondi, L. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J. Hepatol., 2004, 41(3), 421-6.
50. El-Serag, H. B.; Marrero, J. A.; Rudolph, L.; Reddy, K. R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology,2008, 134(6), 1752-63.
51. Khan, M. A.; Combs, C. S.; Brunt, E. M.; Lowe, V. J.; Wolverson, M. K.; Solomon, H.; Collins, B. T.; Di Bisceglie, A. M. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J. Hepatol., 2000, 32(5), 792-7.
52. Porta, C.; De Amici, M.; Quaglini, S.; Paglino, C.; Tagliani, F.;Boncimino, A.; Moratti, R.; Corazza, G. R. Circulating interleukin- 6 as a tumor marker for hepatocellular carcinoma. Ann. Oncol.,2008, 19(2), 353-8.